中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

39 records (took 0.02 seconds)

    Aglycosylated Fc-containing polypeptides with cysteine substitutions
    11.
    发明授权
    Aglycosylated Fc-containing polypeptides with cysteine substitutions 有权
    含半胱氨酸取代的含糖基化的含Fc多肽

    公开(公告)号：US09546203B2

    公开(公告)日：2017-01-17

    申请号：US14209914

    申请日：2014-03-13

    Applicant: Amgen Inc.

    Inventor： Gunasekaran Kannan

    IPC: C07K16/00 ,  C07K14/55 ,  A61K38/00

    CPC classification number: C07K14/55 ,  A61K38/00 ,  C07K16/00 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/524 ,  C07K2317/71 ,  C07K2317/94 ,  C07K2319/21 ,  C07K2319/30 ,  C07K2319/43

    Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.

    Abstract translation: 本文提供了IL-2突变蛋白和IL-2突变蛋白Fc-融合分子，其优先扩增和激活T调节细胞并且适于大规模生产。 本文还提供了缺乏或具有高度降低的效应子功能和高稳定性的变体人IgG1 Fc分子，尽管在N297缺乏糖基化。 此外，本文提供了当在哺乳动物细胞中表达时被糖基化的接头肽。

    Fc variants
    13.
    发明授权
    Fc variants 有权

    公开(公告)号：US11198732B2

    公开(公告)日：2021-12-14

    申请号：US16413810

    申请日：2019-05-16

    Applicant: AMGEN INC.

    Inventor： Zhi Liu ,  Gunasekaran Kannan ,  Wei Yan

    IPC: C07K16/00 ,  C12P21/08 ,  A61K39/395 ,  A61K39/40 ,  C07K16/28 ,  A61K45/06 ,  C07K1/00

    Abstract: Disclosed are Fc-containing proteins comprising a binding region and a variant Fc region that can elicit one or more immune effector function and/or bind to an Fc receptor more effectively than a similar Fc-containing protein comprising a wild type Fc region. Also disclosed are nucleic acids encoding such Fc-containing proteins, methods for making such proteins, and methods of treatment utilizing such proteins.

    Anti-TL1A/anti-TNF-alpha bispecific antigen binding proteins and uses thereof
    14.
    发明授权
    Anti-TL1A/anti-TNF-alpha bispecific antigen binding proteins and uses thereof 有权

    公开(公告)号：US11104745B2

    公开(公告)日：2021-08-31

    申请号：US16062096

    申请日：2016-12-14

    Applicant: AMGEN INC.

    Inventor： Hailing Hsu ,  Gunasekaran Kannan ,  Kenneth W. Walker ,  Michelle Hortter ,  Edward J. Belouski

    IPC: C07K16/46 ,  C07K16/24 ,  A61K39/395 ,  C07K16/28 ,  C12N15/10

    Abstract: The present invention concerns antigen binding proteins that bind TL1A, including bispecific antigen binding proteins (e.g., antibodies) to TL1A and TNF-α. Such bispecific antibodies can be in a tetrameric immunoglobulin format, in which one heavy chain-light chain pair of the antibody is directed to TL1A and the other to TNF-α. The bispecific antigen binding proteins may also be comprised in an IgG-scFv fusion, in which a conventional tetrameric antibody directed to one antigen is fused to a pair of single chain Fv units directed to the other. The bispecific antigen binding protein may also be comprised in an IgG-Fab fusion, in which a Fab molecule that binds to one antigen is fused to each heavy chain of a conventional tetrameric antibody directed to the other antigen. The invention further relates to uses of the anti-TL1A binding proteins and anti-TL1A/anti-TNF-α antigen binding proteins, and pharmaceutical formulations thereof.

Patent Agency Ranking